CINCINNATI, OH--(Marketwired - April 30, 2014) - Medpace Reference Laboratories LLC (MRL),
a Medpace company, announced a significant expansion of its global laboratory footprint, capabilities, and capacity with the opening of a newly built, state-of-the-art central laboratory in Singapore. Medpace Laboratories, Singapore will serve and support new and existing Medpace pharmaceutical clients conducting clinical research in the rapidly expanding Asia Pacific region. With dedicated project management and logistic teams, the central lab is fully integrated into ClinTrak® -- Medpace's proprietary global decision support technology, allowing the transfer of real time data to support clinical studies.
The Singapore facilities have been equipped with identical instrumentation, and use the same reagent systems, calibration, QA process and SOPs. Medpace Laboratories, Singapore will provide routine safety, biomarker and reference methodologies identical to Medpace Reference Laboratories in Cincinnati, USA; Leuven, Belgium; and Beijing, China.
All MRL laboratories are directly supervised by onsite, full-time doctoral level laboratory professionals including MDs and PhDs with board certification in Pathology/Laboratory Medicine. Each MRL location maintains accreditation by the College of American Pathologists (CAP), and NGSP Level 1 and CDC Lipid Standardization (LSP) Part III programs, providing MRL the ability to deliver consistent, identical and highly standardized laboratory analysis. Accreditation by these internationally recognized programs reflect the high standards to which MRL is committed.
ABOUT MEDPACE REFERENCE LABS (MRL)
MRL is a full-service central laboratory with locations in the USA, Belgium, China, and Singapore. MRL uses state-of-the-art instrumentation and methods, which are identical at all MRL global sites. MRL provides production and shipping of specimen collection kits; formally correlated testing menus; customized reporting and delivery options to accommodate international requirements; long-term archival specimen storage; and appropriate quality assurance.
Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, regenerative medicine, and gastrointestinal diseases. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs over 1700 employees and has clinical trial experience in over 45 countries and 6 regions -- the US, Europe, Central and Eastern Europe, India, Asia Pacific, and China. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management.
For more information visit the Medpace website at: www.medpace.com.